他米巴罗汀药理学研究进展 |
| |
引用本文: | 杨立平.他米巴罗汀药理学研究进展[J].中华临床医学杂志,2008,9(7):57-60. |
| |
作者姓名: | 杨立平 |
| |
作者单位: | 湖南省肿瘤医院,湖南长沙410013 |
| |
摘 要: | 本文对他米巴罗汀的药理学进行综述。他米巴罗汀是一个新的维甲酸受体α(RARα)促进剂,在体外可诱导急性早幼粒细胞性白血病基因(PML)分化和成熟,抑制PML增殖。在临床试验中,他米巴罗汀显示了明显的抗肿瘤活性和较好的耐受性。
|
关 键 词: | 他米巴罗汀 急性早幼粒细胞性白血病 药理学 |
Pharmacological Research of tamibarotene |
| |
Abstract: | Pharmacologic and pharmacodynamics of tamibarotene were reviewed in this paper. Tamibarotene is a new RARer agonist, and it successfully induces PML differentiation and maturation in vitro, deterring PML proliferation. In invivo studies, tamibarotene demonstrates antitumor activity and good tolerability. |
| |
Keywords: | Tamibarotene Acute promyelocytic leukemia Pharmacology |
本文献已被 维普 等数据库收录! |
|